CLLS
$8.24
Cellectis S.A. ADR
($.37)
(4.30%)
CLLS
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($1.05)
Revenue:  $12.30 Mil
Thursday
Feb 3
0:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when CLLS reports earnings?
Beat
Meet
Miss

Where is CLLS's stock price going from here?
Up
Flat
Down
Stock chart of CLLS
Analysts
Summary of analysts' recommendations for CLLS
Score
Grade
Pivots
Resistance
$9.28
$8.97
$8.61

$8.30

Support
$7.94
$7.63
$7.27
Tweet
Growth
Description
Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.